title: Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.
abstract: In preclinical studies, drugs that increase cyclic guanosine monophosphate levels have been shown to influence platelet function/aggregation; however, the effect of riociguat on human platelets is unclear. Aspirin, a platelet inhibitor, is likely to be given concomitantly in patients receiving riociguat. It is therefore important to establish clinically whether (1) riociguat affects platelet function and (2) aspirin and riociguat interact. This randomized, open-label, crossover study investigated potential pharmacodynamic and pharmacokinetic interactions between these drugs in healthy male volunteers (N = 18). There were 3 treatment regimens: a single morning dose of riociguat 2.5 mg, aspirin 500 mg on 2 consecutive mornings, and both treatments together, with riociguat given on the second morning. Fifteen participants were available for pharmacodynamic/pharmacokinetic analysis. There was no effect of riociguat alone on bleeding time, platelet aggregation, and serum thromboxane B2 levels. The effects of aspirin on these parameters were not influenced by concomitant administration of riociguat. The pharmacokinetic profile of riociguat showed interindividual variability, which was independent of aspirin coadministration. Six of 17 participants available for safety evaluation reported at least 1 treatment-emergent adverse event. All adverse events were of mild severity, apart from 1 report of moderate headache. No serious adverse events occurred. In conclusion, riociguat demonstrated no clinically relevant pharmacodynamic or pharmacokinetic interactions with aspirin at the doses used in this study in healthy men; coadministration of riociguat and aspirin should therefore not require any dose adjustment for either drug.
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Reiner
authors.initials: R
authors.lastname: Frey
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Reber
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Jörn
authors.initials: J
authors.lastname: Krätzschmar
authors.affiliation: Global Biostatistics, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Sigrun
authors.initials: S
authors.lastname: Unger
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Mück
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Wensing
keywords: bleeding time; platelet aggregation; safety; salicylic acid; soluble guanylate cyclase